Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Blood (2024) 144 (Supplement 1): 225.

https://doi.org/10.1182/blood-2024-204503

Published: 2024

Journal Articles

Clinical Characterization of Fusion Genes in Acute Myeloid Leukemia without Recurrent Genetic Abnormalities

Francesca Guijarro, Marc Dabad, Mònica López-Guerra, Alex Bataller Torralba, Sandra Castaño-Díez, Carlos Jimenez-Vicente, Marta Garrote, José Ramón Álamo Moreno, Marta Pratcorona, Neus Villamor, Dolors Colomer, Silvia Bea, Dolors Costa, Anna Esteve-Codina, Marina Díaz-Beyá, Jordi Esteve

Blood (2023) 142 (Supplement 1): 6008.

https://doi.org/10.1182/blood-2023-188261

Published: 2023

Journal Articles

Chronic Myelomonocytic Leukemia (CMML) with AML Typical Mutations ( NPM1, FLT3 or CEBPA ) Identify a High-Risk CMML Group Independent of Molecular-Cpss

Blood (2023) 142 (Supplement 1): 3231.

https://doi.org/10.1182/blood-2023-173311

Published: 2023

Journal Articles

Validation of ELN 2022 Risk Classification in Patients Diagnosed with AML Undergoing Allogeneic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 4230.

https://doi.org/10.1182/blood-2023-185484

Published: 2023

Journal Articles

Decoding the molecular heterogeneity of pediatric monomorphic post–solid organ transplant lymphoproliferative disorders

Blood (2023) 142 (5): 434–445.

https://doi.org/10.1182/blood.2022019543

Published: 2023

Includes: Supplemental data

Journal Articles

Generation of Richter Transformation Models throughout Chronic Lymphocytic Leukemia Patient-Derived Xenografts: A Clonal Evolution Model

Heribert Playa-Albinyana, Fabian Arenas, Romina Royo, Ariadna Giró, Irene López, Monica Lopez-Guerra, Sílvia Beà, Elías Campo, Ferran Nadeu, Dolors Colomer

Blood (2022) 140 (Supplement 1): 1534–1535.

https://doi.org/10.1182/blood-2022-163211

Published: 2022

Journal Articles

RAS Mutations in Adult Acute Myeloid Leukemia (AML). Frequency, Mutational Spectrum, and Identification of a Comutation Bias for KRAS K117 ( TET2 / ASXL1 )

Blood (2022) 140 (Supplement 1): 11821–11823.

https://doi.org/10.1182/blood-2022-164718

Published: 2022

Journal Articles

Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia

David F. Moreno, Sara Paz, Mari-Pau Mena, Monica Lopez-Guerra, Aina Oliver-Caldes, Anthony M Battram, Luis Gerardo Rodríguez-Lobato, Natalia Tovar, M. Teresa Cibeira, Raquel Jiménez-Segura, Joan Bladé Creixenti, Laura Rosinol, Dolors Colomer, Carlos Fernandez de Larrea

Blood (2021) 138 (Supplement 1): 462.

https://doi.org/10.1182/blood-2021-147168

Published: 2021

Journal Articles

Myeloproliferative/Myelodysplastic Neoplasms Presenting All Diagnostic Criteria of Chronic Myelomonocytic Leukemia but with Absolute Peripheral Blood Monocytosis 0.5-1× 10 9 /L Should be Classified As CMML

Sandra Castaño-Díez, Monica Lopez-Guerra, PhD, Daniel Esteban, Francesca Guijarro, MD, Alex Bataller Torralba, MD, Paola Charry, MD, Carlos Castillo, MD, Carlos Jiménez-Vicente, MD, Colomer Dolors, María Rozman, MD, Jordi Esteve, Marina Diaz-Beyá, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-142819

Published: 2020

Journal Articles

Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012)

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-140670

Published: 2020

Journal Articles

Emergence of NPM1 Wild-Type Myeloid Neoplasms after Chemotherapy for Acute Leukemia with NPM1 Mutation: Proposed Mechanisms of Clonal Evolution

Sandra Castaño-Díez, Monica Lopez-Guerra, PhD, Francesca Guijarro, MD, Alex Bataller Torralba, MD, Daniel Esteban, Carlos Castillo, MD, Carlos Jiménez-Vicente, MD, Paola Charry, MD, Colomer Dolors, María Rozman, MD, Jordi Esteve, Marina Diaz-Beyá, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-142740

Published: 2020

Journal Articles

Splenic Marginal Zone Lymphoma: Risk of Transformation, Clinico-Biological Features at Transformation and Prognosis

Blood (2019) 134 (Supplement_1): 4015.

https://doi.org/10.1182/blood-2019-127199

Published: 2019

Journal Articles

The U1 Spliceosomal RNA: A Novel Non-Coding Hotspot Driver Mutation Independently Associated with Clinical Outcome in Chronic Lymphocytic Leukemia

Blood (2019) 134 (Supplement_1): 847.

https://doi.org/10.1182/blood-2019-130052

Published: 2019

Journal Articles

Triple Negative Myelofibrosis and Myelodysplastic Syndrome with Fibrosis: Clinico-Biological Characterization and Correlation with Gene Mutations

Juan Gonzalo Correa, MD, Alberto Alvarez-Larrán, MD PhD, Monica Lopez-Guerra, PhD, Juan Carlos Hernandez Boluda, MD PhD, Mar Tormo, MD PhD, María Rozman, MD PhD, Daniel Martínez, MD, Dolors Colomer, PhD, Jordi Esteve, MD PhD, Francisco Cervantes, MD PhD

Blood (2018) 132 (Supplement 1): 4299.

https://doi.org/10.1182/blood-2018-99-115888

Published: 2018

Journal Articles

Targeting IRAK4 Disrupts Inflammatory Pathways and Delays Tumor Development in Chronic Lymphocytic Leukemia

Neus Giménez Carabaza, B.Pharm, Rosich Laia, PhD, Schulz Ralph, MS, Higashi Morihiro, MD, Marta Aymerich, Neus Villamor, PhD, Julio Delgado, MD, Manel Juan, MD, Monica Lopez-Guerra, PhD, Elias Campo, Martina Seiffert, PhD, Dolors Colomer, PhD

Blood (2018) 132 (Supplement 1): 2650.

https://doi.org/10.1182/blood-2018-99-115999

Published: 2018

Journal Articles

Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol)

Blood (2018) 132 (Supplement 1): 1385.

https://doi.org/10.1182/blood-2018-99-110895

Published: 2018

Journal Articles

Linear and Branching Progression of Chronic Lymphocytic Leukemia (CLL) Under PI3K Inhibition (PI3Ki)

Julio Delgado, MD, Silvia Bea, Rafael Valdes-Mas, Blanca Gonzalez-Farre, Jesus Gutierrez-Abril, Monica Lopez-Guerra, Alba Navarro, Marta Aymerich, Neus Villamor, Magda Pinyol, Armando Lopez-Guillermo, Carlos Lopez-Otin, Xose Puente, Elias Campo, MD PhD

Blood (2017) 130 (Supplement 1): 3000.

https://doi.org/10.1182/blood.V130.Suppl_1.3000.3000

Published: 2017

Journal Articles

Notch1 Signaling in NOTCH1 -Mutated Mantle Cell Lymphoma Depends on DLL4 and Is a Potential Target for Specific Antibody Therapy

Elisabeth Höring, MD, Berta Colom Sanmarti, Silvia Xargay-Torrent, PhD, Walter E Aulitzky, MD, Heiko van der Kuip, PhD, Elias Campo, Mónica López-Guerra, PhD, Dolors Colomer, PhD

Blood (2016) 128 (22): 1846.

https://doi.org/10.1182/blood.V128.22.1846.1846

Published: 2016

Journal Articles

The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78

Gaël Roué, Patricia Pérez-Galán, Ana Mozos, Mónica López-Guerra, Sílvia Xargay-Torrent, Laia Rosich, Ifigènia Saborit-Villarroya, Emmanuel Normant, Elias Campo, Dolors Colomer

Blood (2011) 117 (4): 1270–1279.

https://doi.org/10.1182/blood-2010-04-278853

Published: 2011

Includes: Supplemental data

Journal Articles

Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM

Roberto Alonso, Mónica López-Guerra, Ramanda Upshaw, Shanta Bantia, Caroline Smal, Françoise Bontemps, Chantal Manz, Thomas Mehrling, Neus Villamor, Elias Campo, Emili Montserrat, Dolors Colomer

Blood (2009) 114 (8): 1563–1575.

https://doi.org/10.1182/blood-2009-02-207654

Published: 2009

Includes: Supplemental data

NARROW

Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Clinical Characterization of Fusion Genes in Acute Myeloid Leukemia without Recurrent Genetic Abnormalities

Chronic Myelomonocytic Leukemia (CMML) with AML Typical Mutations ( NPM1, FLT3 or CEBPA ) Identify a High-Risk CMML Group Independent of Molecular-Cpss

Validation of ELN 2022 Risk Classification in Patients Diagnosed with AML Undergoing Allogeneic Hematopoietic Cell Transplantation

Decoding the molecular heterogeneity of pediatric monomorphic post–solid organ transplant lymphoproliferative disorders

Generation of Richter Transformation Models throughout Chronic Lymphocytic Leukemia Patient-Derived Xenografts: A Clonal Evolution Model

RAS Mutations in Adult Acute Myeloid Leukemia (AML). Frequency, Mutational Spectrum, and Identification of a Comutation Bias for KRAS K117 ( TET2 / ASXL1 )

Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia

Myeloproliferative/Myelodysplastic Neoplasms Presenting All Diagnostic Criteria of Chronic Myelomonocytic Leukemia but with Absolute Peripheral Blood Monocytosis 0.5-1× 10 9 /L Should be Classified As CMML

Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012)

Emergence of NPM1 Wild-Type Myeloid Neoplasms after Chemotherapy for Acute Leukemia with NPM1 Mutation: Proposed Mechanisms of Clonal Evolution

Splenic Marginal Zone Lymphoma: Risk of Transformation, Clinico-Biological Features at Transformation and Prognosis

The U1 Spliceosomal RNA: A Novel Non-Coding Hotspot Driver Mutation Independently Associated with Clinical Outcome in Chronic Lymphocytic Leukemia

Triple Negative Myelofibrosis and Myelodysplastic Syndrome with Fibrosis: Clinico-Biological Characterization and Correlation with Gene Mutations

Targeting IRAK4 Disrupts Inflammatory Pathways and Delays Tumor Development in Chronic Lymphocytic Leukemia

Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol)

Linear and Branching Progression of Chronic Lymphocytic Leukemia (CLL) Under PI3K Inhibition (PI3Ki)

Notch1 Signaling in NOTCH1 -Mutated Mantle Cell Lymphoma Depends on DLL4 and Is a Potential Target for Specific Antibody Therapy

The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78

Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only